

Page 1- Supplemental Information: Deal Related Amortization

Page 2 - Supplemental Information: FY18 Constant Currency Growth Rates

Page 3 - Historical revenue by Product Category

## Deal Related Amortization

### Supplemental Information - Deal Related Amortization

(\$ Millions, except per Share Data)

	FY15	FY16	FY17	Q118	Q218
Deal Amortization	\$ 30	\$ 28	\$ 27	\$ 6	\$ 7
Tax Effect of Deal Amortization	\$ (9)	\$ (8)	\$ (8)	\$ (2)	\$ (2)
Deal Amortization, EPS	\$ 0.40	\$ 0.40	\$ 0.38	\$ 0.09	\$ 0.09

**FY18 Product Category Growth Rates in Reported and Constant Currency**

	<b>Q1 % Growth - Reported Currency</b>	<b>Q1 % Growth - Constant Currency</b>	<b>Q2 % Growth - Reported Currency</b>	<b>Q2 % Growth - Constant Currency</b>
Plasma	4.0%	4.3%	6.0%	5.7%
Hospital	6.1%	6.9%	3.5%	3.4%
Hemostasis Management	14.8%	16.7%	10.1%	10.4%
Cell Processing	1.0%	1.5%	(0.7%)	(0.8%)
Blood Center	(7.6%)	(7.1%)	(3.4%)	(3.8%)
<b>Total Revenue</b>	<b>0.5%</b>	<b>1.0%</b>	<b>2.3%</b>	<b>2.1%</b>

**Historical Product Category Revenue in Reported Currency**

(\$ Millions)

	<b>Q117</b>	<b>Q217</b>	<b>Q317</b>	<b>Q417</b>	<b>FY17</b>	<b>Q118</b>	<b>Q218</b>
<b>Total Revenue</b>	\$ 210	\$ 220	\$ 228	\$ 228	\$ 886	\$ 211	\$ 225
<b><i>By Product Category:</i></b>							
<b>Plasma</b>	\$ 98	\$ 104	\$ 108	\$ 101	\$ 411	\$ 101	\$ 110
<b>Hospital</b>	\$ 41	\$ 42	\$ 43	\$ 45	\$ 171	\$ 44	\$ 44
<b>Hemostasis Management</b>	\$ 15	\$ 16	\$ 17	\$ 18	\$ 66	\$ 18	\$ 18
<b>Cell Processing</b>	\$ 26	\$ 26	\$ 26	\$ 27	\$ 105	\$ 26	\$ 26
<b>Blood Center</b>	\$ 71	\$ 74	\$ 77	\$ 82	\$ 304	\$ 66	\$ 71